Eli Lilly and Company (NYSE:LLY) Shares Climb 2.8% – What’s Next?

Eli Lilly and Company (NYSE:LLY)’s stock price was up 2.8% during mid-day trading on Thursday. The company traded as high as $1,197.79 and last traded at $1,183.2170. Approximately 2,404,559 shares changed hands during mid-day trading, a decline of 20% from the average session volume of 3,013,247 shares. The stock had previously closed at $1,150.99.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA approves once-weekly insulin: The FDA approved Onswik (insulin efsitora alfa) for adults with type 2 diabetes. The treatment offers an alternative to daily basal-insulin injections and could improve convenience and adherence. Approval was supported by Lilly’s Phase 3 QWINT program, which involved more than 3,400 patients. US FDA approves Lilly’s once-weekly insulin injection for type 2 diabetes
• Positive Sentiment: New China drug-discovery partnership: Lilly agreed to collaborate with InnoCare Pharma on as many as five undisclosed drug targets. The agreement includes $100 million upfront and could generate up to approximately $3.35 billion in payments, expanding Lilly’s early-stage oncology and autoimmune pipeline. China’s InnoCare, Eli Lilly sign collaboration deal worth up to $3.35 billion
• Positive Sentiment: Obesity franchise momentum: Lilly’s CEO said Foundayo is capturing about one-third of new oral GLP-1 prescriptions and approximately 70% of new senior patients following expanded Medicare coverage. Lilly also broke ground on a planned $6.5 billion Houston manufacturing facility to support future demand.
• Neutral Sentiment: Long-term bullish commentary: Home Depot co-founder Ken Langone said LLY could reach $2,000 within three to four years. The comment may reinforce investor optimism but is not company guidance or an analyst estimate. Lilly is already trading near its 12-month high and at a premium valuation.
• Negative Sentiment: Competitive and trading risks: Viking Therapeutics reported promising maintenance data for its obesity drug, suggesting less-frequent dosing could challenge Lilly’s weekly injectable products over time. Separately, recent disclosures show several Lilly executives sold shares, although insider selling was not linked to a change in the company’s outlook.

Analysts Set New Price Targets

Several equities research analysts recently commented on LLY shares. Wells Fargo & Company increased their price target on Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Bank of America lifted their target price on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a “buy” rating in a report on Friday, July 10th. Berenberg Bank set a $1,400.00 price target on shares of Eli Lilly and Company and gave the stock a “buy” rating in a research report on Tuesday, September 15th. Guggenheim increased their target price on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a “buy” rating in a report on Friday, September 18th. Finally, UBS Group set a $1,376.00 target price on Eli Lilly and Company in a report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $1,308.39.

Eli Lilly and Company Price Performance

The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The firm has a market capitalization of $1.11 trillion, a price-to-earnings ratio of 39.71, a P/E/G ratio of 1.44 and a beta of 0.50. The company has a fifty day moving average price of $1,176.78 and a two-hundred day moving average price of $1,080.70.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, beating analysts’ consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The business had revenue of $22.97 billion during the quarter, compared to analysts’ expectations of $20.82 billion. During the same period in the prior year, the company earned $6.31 earnings per share. The business’s revenue was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, equities research analysts expect that Eli Lilly and Company will post 36.54 EPS for the current fiscal year.

Insider Activity

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 2,000 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the transaction, the chief accounting officer owned 1,526 shares in the company, valued at approximately $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the sale, the executive vice president directly owned 11,875 shares in the company, valued at approximately $14,131,250. This represents a 29.63% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock valued at $15,958,170 over the last quarter. Corporate insiders own 0.14% of the company’s stock.

Institutional Investors Weigh In On Eli Lilly and Company

A number of large investors have recently added to or reduced their stakes in the business. Osbon Capital Management LLC purchased a new stake in shares of Eli Lilly and Company in the fourth quarter valued at $25,000. Basso Capital Management L.P. acquired a new stake in shares of Eli Lilly and Company during the 4th quarter worth $30,000. Maseco LLP lifted its stake in shares of Eli Lilly and Company by 466.7% in the 1st quarter. Maseco LLP now owns 34 shares of the company’s stock valued at $31,000 after purchasing an additional 28 shares in the last quarter. Aventus Investment Advisors Inc. grew its stake in Eli Lilly and Company by 270.0% during the first quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company’s stock worth $34,000 after buying an additional 27 shares during the period. Finally, Marshall & Sterling Wealth Advisors Inc. increased its holdings in Eli Lilly and Company by 60.0% in the 1st quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock valued at $37,000 after purchasing an additional 15 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its portfolio includes treatments for diabetes and obesity, oncology, immunology, neuroscience, cardiovascular disease and other areas of significant unmet medical need.

The company’s products include Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, and insulin products such as Humalog. Lilly also markets Verzenio for certain breast cancers and Kisunla for the treatment of early symptomatic Alzheimer’s disease.